ArticleCureus2026
Effect of Residual Insulin Secretion on Glycaemic Control Among Young Cameroonian Individuals With Type 1 Diabetes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycaemic Variability and C-Peptide in Bangladeshi Children, Adolescents, and Young Adults With Diabetes: A Prospective Study.Endocrinology, diabetes & metabolism · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The objective of the article is to determine the effect of residual insulin secretion on glycaemic control among young Cameroonian individuals diagnosed with type 1 diabetes (T1D). Methods We conducted a hospital-based cross-sectional study from April to August 2022. Forty-two children and adolescents diagnosed with T1D attending the paediatric diabetes clinic of the Yaoundé Central Hospital in Cameroon were enrolled in the study. Residual insulin secretion was assessed by measuring plasma C-peptide concentrations before and after a mixed meal tolerance test (MMTT) using an enzyme-linked immunosorbent assay (ELISA) method. Glycosylated haemoglobin (HbA1c) was measured by boronate affinity chromatography with the HemoCue® HbA1c 501 analyser. Residual insulin secretion was classified as absent (<0.033 nmol/L), low (0.033-0.2 nmol/L), or high (≥0.2 nmol/L) based on stimulated C-peptide levels. Clinical characteristics and HbA1c values were compared between participants with high residual insulin secretion and the rest of the cohort. Results The median age of participants was 18.5 (16-24) years, with a median diabetes duration of three (2-10) years and a median HbA1c of 8.4% (6.9-11.3). Stimulated C-peptide was detectable (≥0.033 nmol/L) in 25 (60%) participants and above 0.2 nmol/L in 12 (29%). Compared with those without or with low residual insulin secretion, participants with high secretion had a shorter median duration of diabetes (two (IQR: 1-4) vs six (IQR: 2-11) years; p=0.009), lower median daily insulin doses (0.7 (IQR: 0.4-0.8) vs 0.9 (IQR: 0.7-1.3) IU/kg; p=0.008), fewer median episodes of severe hypoglycaemia (zero (IQR: 0-2) vs four (IQR: 1-6); p=0.006), higher median BMI (26.1 (IQR: 25-29.3) vs 22.9 (IQR: 19.4-25.6) kg/m²; p=0.02), and lower median HbA1c levels (7.1 (IQR: 6.1-8.3) vs 9.1 (IQR: 8.1-12.2)%; p=0.01). Conclusion High residual insulin secretion was observed in nearly one-third of young Cameroonians with T1D and was strongly associated with better glycaemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.